The sensitizing side of Onyx-015

Gene Therapy

Volumn 12, Issue 5, 2005, Pages 386-387

  Wildner, Oliver ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; IMATINIB; MITOMYCIN; ONYX 015; PROTEIN P53; VIRUS DNA;

ADENOVIRUS; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CYTOLYSIS; DNA REPLICATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; GENETIC MANIPULATION; HUMAN; MAXIMUM TOLERATED DOSE; NONHUMAN; NOTE; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS VIRULENCE; WILD TYPE; ANIMAL; GENE THERAPY; GENETICS; METHODOLOGY; SARCOMA;

ADENOVIRIDAE; DNA VIRUSES; ONYX;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; GENE THERAPY; HUMANS; SARCOMA;

EID: 15444377848     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302429     Document Type: Note

References (28)

1. Wildner O. Oncolytic viruses as therapeutic agents. Ann Med 2001; 33: 291-304.
2. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001: 781-787.
3. Shenk T. Adenoviridea. In: Fields BN, Knipe DM, Howley PM (eds). Fields' Virology. Lippincott-Raven: Philadelphia, 1996, pp 2111-2148.
4. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
5. Heise C et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-645.
6. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus; early 1B protein. Nature 1992; 357: 82-85.
7. Yew PR, Kao CC, Berk AJ. Dissection of functional domains in the adenovirus 2 early 1B 55K polypeptide by suppressor-linker insertional mutagenesis. Virology 1990; 179: 795-805.
8. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107-121.
9. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 1998; 4: 1068-1072.
10. Rothmann T et al. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998; 72: 9470-9478.
11. Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 1998; 72: 9479-9490.
12. Goldsmith KT, Dion LD, Curiel DT, Garver Jr RI. Trans E1 component requirements for maximal replication of E1-defective recombinant adenovirus. Virology 1998; 248: 406-419.
13. Turnell AS, Grand RJ, Gallimore PH. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J Virol 1999; 73: 2074-2083.
14. Harada JN, Berk AJ. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 1999; 73: 5333-5344.
15. Hay JG et al. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Hum Gene Ther 1999; 10: 579-590.
16. Vollmer CM et al. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res 1999; 59: 4369-4374.
17. Wildner O, Morris JC. The role of the E1B 55kDa gene in oncolytic adenoviral vectors expressing HSV-tk: assessment of anti-tumor efficacy and toxicity. Cancer Res 2000; 60: 4167-4174.
18. Morris JC, Wildner O. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol Ther 2000; 1: 56-62.
19. Wildner O, Morris JC. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses. J Gene Med 2000; 2: 353-360.
20. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Therapy 2001; 8: 89-98.
21. Khuri FR et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
22. Heise C, Lemmon M, Kirn D. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res 2000; 6: 4908-4914.
23. Nemunaitis J et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-298.
24. Wein LM, Wu JT, Kirn DH. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 2003; 63: 1317-1324.
25. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
26. Brennan M, Alektiar K, Maki R. Sarcomas of soft tissue and bone: soft tissue sarcoma. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. Williams and Wilkins: Philadelphia, 2001, pp 1841-1891.
27. Borden EC et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 2003; 9: 1941-1956.
28. Joensuu H et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.